Balinsus Bio receives a “buy” stock rating based on clinical trial progress

On Wednesday, Wainwright HC maintained a positive stance on shares of Barinthus Biotherapeutics (NASDAQ:BRNS), reiterating a Buy rating with a $5.00 price target and a $5.00 price target. The company’s optimism is based on the recent completion of patient enrollment in the Phase 2b HBV003 trial of VTP-300, a treatment for chronic hepatitis B (CHB). The trial successfully enrolled 121 subjects and expects results in the fourth quarter of 2024.

Progress in this trial is encouraging, with interim data published in June 2024 showing sustained reductions in HBsAg levels in patients treated with VTP-300 and low-dose nivolumab. . For patients with baseline HBsAg levels ≤200 IU/mL, a significant proportion were eligible for discontinuation of nucleoside analog therapy at the end of treatment.

Additionally, some of these patients remained untreated for long periods of time, with two achieving undetectable HBsAg levels for at least 16 weeks.

The treatment also has a good safety profile, with no serious adverse events (SAEs) or high-grade adverse events (AEs) directly related to the treatment reported. Although thyroid dysfunction was the most common treatment-related AE, affecting a small proportion of participants, subsequent normal thyroid function was observed in the majority of those cases.

In addition to the HBV003 study, the company has completed enrollment in the Phase 1 PCA001 study of VTP-850 for elevated prostate-specific antigen levels in men. Despite completion, the company is shifting its focus away from the VTP-850 program, with data expected in the first half of 2025.

Wainwright HC’s analysis suggests that given the ability of VTP-300 to significantly reduce HBsAg levels and allow discontinuation of other treatments, it may become an important element in functional treatment plans for CHB. It suggests something. The company’s reiterated Buy rating and price target reflect confidence in Balinsus Biotherapeutics’ ongoing clinical development.

In other recent news, Balinsus Biotherapeutics has made significant progress in its clinical trials and corporate structure. The biopharmaceutical company has completed enrollment in two pivotal trials, HBV003 and PCA001, focused on treating chronic hepatitis B and prostate cancer, respectively. The company also initiated the Phase 1 AVALON trial of VTP-1000, an investigational immunotherapy for celiac disease.

Additionally, Balinsus Bio has undergone internal restructuring, promoting Graham Griffiths to Chief Operating Officer and welcoming Dr. Leon Hoftman as the new Chief Medical Officer. The company also announced 25% layoffs, which are expected to extend its cash flow into the second quarter of 2026.

Based on these developments, Wainwright HC maintained its rating on Balinthus Biotherapeutics at “buy.” A recent change in the company’s strategic focus to prioritize the development of VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease led to this decision.

Finally, Barinthus Biotherapeutics reported mixed results from the APOLLO trial of VTP-200, a treatment for cervical lesions associated with high-risk HPV infections. These are the latest results of the company’s ongoing research and restructuring efforts.

Investment Pro Insights

While Wainwright HC maintains a positive outlook on Barinthus Biotherapeutics (NASDAQ:BRNS), recent financial data from InvestingPro paints a more mixed picture. The company’s market capitalization is $46.51 million, reflecting its current status as a small-cap biopharmaceutical company.

InvestingPro Tips highlights that BRNS has more cash than debt on its balance sheet, which could give it some financial flexibility as clinical trials progress. But the company is rapidly running out of cash, a common challenge for biotech companies in the development stage.

The stock price has fallen significantly over the past 6 months, with a total return of -50.21%. This decline is consistent with a tip from InvestingPro that indicates BRNS is trading near its 52-week low. Despite these challenges, analysts have set a fair value target of $7.00, suggesting upside potential if the company’s clinical trials produce positive results.

For investors looking for a more comprehensive analysis, InvestingPro offers 11 additional tips on BRNS to help you better understand the company’s financial health and market position.

This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.